6,7-Dichloro-3-Hydroxy-2-Quinoxalinecarboxylic Acid

6,7-Dichloro-3-Hydroxy-2-Quinoxalinecarboxylic Acid

SCHEMBL6697845

O=C(O)c1nc2cc(Cl)c(Cl)cc2[nH]c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 4/20 1.00
GRIN3B O60391 4/20 1.00
GRIA1 P42261 4/20 1.00
GRIA2 P42262 4/20 1.00
GRIA3 P42263 4/20 1.00
GRIA4 P48058 4/20 1.00
GRIN1 Q05586 4/20 1.00
GRIN2A Q12879 4/20 1.00
GRIN2B Q13224 4/20 1.00
GRIN2C Q14957 4/20 1.00
GRIN3A Q8TCU5 4/20 1.00
GRIK1 P39086 2/20 1.00
GRIK2 Q13002 2/20 1.00
GRIK3 Q13003 2/20 1.00
GRIK4 Q16099 2/20 1.00
GRIK5 Q16478 2/20 1.00
LMNA P02545 2/20 1.00
PRKAG1 P54619 6/20 0.51
PRKAA2 P54646 6/20 0.51
PRKAB1 Q9Y478 6/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11349897 0.88 GRIN2D (0.78) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL11349852 0.88 GRIN2D (0.78) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL9703926 0.85 GRIN2D (0.74) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL9705832 0.85 GRIN2D (0.74) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL6603624 0.83 GRIN2D (0.70) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL6608200 0.83 GRIN2D (0.70) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL9703949 0.83 GRIN2D (0.70) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL9704899 0.81 GRIN2D (0.71) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL11256884 0.81 GRIN2D (0.68) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL9704358 0.81 GRIN2D (0.68) GRIN2DGRIN3BGRIA1GRIA2GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224954-A1 Substituted 1H-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds GRUNENTHAL GMBH (DE) 2004-11-11 US claimed
EP-0029658-A1 Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them ELI LILLY AND COMPANY (US) 1981-06-03 EP claimed
US-4252954-A VIRICIDES ELI LILLY AND COMPANY (US) 1981-02-24 US claimed
US-20170072005-A1 COMBINATIONS OF NMDAR MODULATING COMPOUNDS UNIV NORTHWESTERN (US) 2017-03-16 US disclosed
US-20170072005-A1 COMBINATIONS OF NMDAR MODULATING COMPOUNDS UNIV NORTHWESTERN (US) 2017-03-16 US disclosed
US-20040224954-A1 Substituted 1H-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds GRUNENTHAL GMBH (DE) 2004-11-11 US disclosed
US-4355030-A Antiviral combinations ELI LILLY AND COMPANY (US) 1982-10-19 US disclosed
US-4289773-A ETHYL 6,7-DIBROMO-3,4-DIHYDRO-3-OXOQUINOXALINE CARBOXYLATE AND A HINDERED AMINE ELI LILLY AND COMPANY (US) 1981-09-15 US disclosed
EP-0029658-A1 Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them ELI LILLY AND COMPANY (US) 1981-06-03 EP disclosed
US-4271162-A ETHYL 6,7-DICHLORO-3,4-DIHYDRO-3-ONOQUINOXALINE CARBOXYLATE AND 1-AMINOADAMANTANE ELI LILLY AND COMPANY (US) 1981-06-02 US disclosed
US-4264600-A VIRICIDES ELI LILLY AND COMPANY (US) 1981-04-28 US disclosed
US-4252954-A VIRICIDES ELI LILLY AND COMPANY (US) 1981-02-24 US disclosed
EP-0020836-A1 Antiviral combinations ELI LILLY AND COMPANY (US) 1981-01-07 EP disclosed
US-4210647-A INFLUENZA VIRUS, ETHYL 6,7-DIBROMO-3,4-DIHYDRO-3-OXO-2-QUINOXALINECARBOXYLATE, 1-AMINOADAMANTANE ELI LILLY AND COMPANY (US) 1980-07-01 US disclosed
EP-0010426-A1 Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines, novel such quinoxalines and processes for the production thereof ELI LILLY AND COMPANY (US) 1980-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170072005-A1 COMBINATIONS OF NMDAR MODULATING COMPOUNDS GRIN1, GRIN2A, GRIN3A GRIN2D 15/4885GRIN3B 5/4885GRIA1 11/4885
US-20040224954-A1 Substituted 1H-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds NQO2, NQO1, CYP2C8 GRIN2D 1540/4885GRIN3B 1596/4885GRIA1 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.